Lung Cancer

The FDA has approved capmatinib for the treatment of patients with non–small cell lung cancer.

Jean Lopategui, MD, discusses the evolution of molecular testing in non–small cell lung cancer.

David P. Carbone, MD, PhD, discusses a study evaluating acquired resistance to osimertinib in non–small cell lung cancer.

Terence M. Williams, MD, PhD, discusses research examining a serum biomarker, neutrophil-to-lymphocyte ratio, in non–small cell lung cancer.

Edward B. Garon, MD, MS, discusses the importance of the GEOMETRY mono-1 study in patients with advanced NSCLC who harbor MET exon 14 skipping mutations.

The past 2 decades have been transformative for the treatment of non–small cell lung cancer; two-thirds of patients have been found to harbor molecular drivers, and a growing proportion of these are now targetable with FDA-approved drugs.

Circulating tumor DNA may be a biomarker for the detection of postsurgical minimal residual disease and for determining the clonality of relapsing disease.

Adoptive cell transfer with tumor-infiltrating lymphocytes was found to be feasible, have a manageable toxicity profile, and expanded in 95% of patients with metastatic non–small cell lung cancer who had disease progression on nivolumab (Opdivo).

Patients with pretreated non–small cell lung cancer and EGFR exon 20 insertions demonstrated a 68.7% disease control rate while on poziotinib systemic therapy.

Results from the GEOMETRY mono-1 study demonstrated antitumor efficacy of and deep and durable responses with capmatinib in 97 patients with advanced non–small cell lung cancer who harbor MET exon 14 mutations.

Mobocertinib (TAK-788) has received an FDA breakthrough therapy designation for the treatment of patients with EGFR exon 20-mutant non–small cell lung cancer.

The PD-1 inhibitor cemiplimab significantly improved overall survival as a frontline treatment for patients with high–PD-L1 non–small cell lung cancer.

The National Medical Products Administration of China has accepted an application for the PD-1 inhibitor sintilimab injection for use in combination with pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer.

The China National Medical Products Administration has accepted a supplemental new drug application for the PD-1 inhibitor tislelizumab for use in combination with chemotherapy for the first-line treatment of patients with advanced squamous non–small cell lung cancer.

Nivolumab combined with ipilimumab significantly improved overall survival versus chemotherapy in previously untreated patients with malignant pleural mesothelioma.

Join oncologists nationwide who have learned from the top leaders in the lung cancer field as they share their insights on coronavirus disease 2019 and how the pandemic is poised to have a significant impact on lung cancer treatment and the health care system. Join us Thursday, May 28, 2020 at 8 PM EST.

The PD-1 inhibitor tislelizumab combined with frontline chemotherapy significantly improved progression-free survival versus chemotherapy alone in patients with nonsquamous non–small cell lung cancer.